Ana Fiszbein recently received a Massachusetts Life Science Center (MLSC) grant. Her proposal is titled, “Elucidating the role of G9a alternative splicing in breast cancer to develop novel targeted therapies.”
From Dr. Fiszbein:
“Our goal is to elucidate the roles of G9a alternative splicing in breast cancer, and breast cancer recurrences, and develop novel targeted therapies based on antisense oligonucleotides to inhibit tumor growth with lower toxicity. We plan to use a combination of high-throughput, functional genomics, and molecular approaches to explore key aspects of G9a-targeted anti-cancer therapies.”
Congratulations, Ana!
